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Introduction 
~ i s - [ P t C l ~ ( N H ~ ) ~ l  a n d  second-generation analogues are used 
as ant icancer  agents.2 Biologically active components  such  as 
hormones) or 1,2-diphenyl-substituted ethylenediamines act ing 
as estrogen-receptor binding molecules4 have been introduced into 
Pt(I1) complexes in order to facilitate t h e  selective transport into 
cancerous cells. Platinum( 11)-Ocatecholato complexes have been 
bound t o  steroidss Chela t ing  diamine functions have been in- 
troduced into t h e  ring A or D of steroids and coordinated t o  
Pt(II).6 Kidani recently reported Pt(I1) complexes in which t h e  
hormone is bound to Pt(I1) by oxygen functions on t h e  r ing D.' 
Gandolf i  incorporated hormone molecules into the malonate  
moiety as the leaving group.* We have a t tached  hormones t o  
Pt(I1) complexes through coordinated amino acids as esters or 
 amide^.^ The amides  were prepared from amino-derivatized 
estrone and estradiol. 
Several neutral mixed amine compounds cis-[PtCl,(NH,)(am)] 
show ant i tumor  activity.I0 It has been shown t h a t  cationic 
mixed-amine complexes cis-[PtCI(NH,),(am)]+ Ii and related 
cationic species,12 the nonclassical analogues of cisplatin, are active 
against  several types of tumors;  also, negatively charged  com- 
pounds [PtCl,(am)]- (am = NH3 or caffeine)13P a n d  [Pt(am),- 
(phosphono carboxylate]-i3b proved to be active. For this reason 
we have prepared cis-[PtCI2(NH3)(am)] and C ~ ~ - [ P ~ C I ( N H ) ) ~ -  
(am)]CI complexes with 3-(2-aminoethoxy)estrone (la) and 3- 
(2-aminoethoxy)estradiol ( lb)  as amines. 
Experimental Section 
Starting Materials and Physical Methods. The complex K[PtCI,(N- 
H,)] was prepared according to Elleman" and Dhara,15 cis-[PtCI,- 
(NH,),] was obtained from Prof. B. Lippert, Dortmund University, and 
K2[PtCI,] was obtained from Degussa AG, Wolfgang. Melting points 
were determined on a Melt-Temp apparatus and are uncorrected. IR 
spectra were performed on a Perkin-Elmer Model 325 spectrometer 
(4000-200 cm-l) in KBr pellets. IH N M R  spectra were recorded on a 
JEOL GSX-270 instrument in DMF-d,; 19% N M R  spectra were ob- 
tained on a AC 200 Bruker spectrometer in DMF-d, solutions. Con- 
ductivity was measured on a Hanna Instrument HI  8733 conductivity 
meter in DMF solutions. All reactions were carried out under nitrogen 
in absolute solvents. 
Preparation of Complexes. cis-[PtCI,(NH,)(am)] ( 2 4 .  3-(2- 
Aminoeth0xy)estrone (la)9 (81.4 mg), (0.26 mmol) dissolved in DMF 
(2 mL) was slowly added to a solution of K[PtCI,(NH,)] (94 mg, 0.26 
mmol) in DMF ( 5  mL) at  60 OC. The mixture was heated for 3 h a t  70 
OC and for I h at 80 OC. To monitor the reaction, a drop of solution was 
evaporated and chromatographed on TLC (aluminum oxide, neutral, 
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Merck, Type E, 60 FU4) using CHCI,-EtOH (9A0.5) as  eluent. When 
the free hormone had disappeared on TLC, the solution was cooled and 
filtered from KCI, concentrated to dryness, and triturated once with 
water and twice with ethanol. An analytical sample was prepared by 
redissolving the yellow product in a minimum volume of D M F  and 
precipitating it with EtOAc: Yield 124 mg (80%); mp 190 OC dec. Anal. 
Calcd for C20H30CI,N202Pt: C, 40.28; H,  5.07; N,  4.70. Found: C, 
40.17; H,  5.18; N, 4.71. 
2b was prepared by the same procedure, which gave 122 mg (78%) 
of product, mp 194 OC dec. Anal. Calcd for C20H32C12N202Pt: C, 
40.14; H,  5.39; N,  4.68. Found: C, 40.48; H,  5.17; N, 4.41. 
[PtCI(NH3)z(am)lCl (39) and tram-(PtCl,(NH,)(am)] (49). The 
hormone (la) (520 mg, 1.66 mmol) was dissolved in D M F  (IO mL) and 
slowly added to a solution of C ~ S - [ P ~ C I ~ ( N H ~ ) ~ ]  (500 mg, 1.66 mmol) in 
DMF (20 mL, 65 "C). The reaction was stirred for 3 h a t  75 OC and 
for 5 h at  85 OC and monitored by TLC. After cooling, a small amount 
of unsoluble white [Pt(NH,),(am)]Cl, (Sa) was removed by centrifu- 
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Eur. J .  Med. Chem. 1985, 20, 327. (c) Bersanetti, E.; Pasini, A.; 
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gation; the solvent was evaporated and the residue triturated with EtOAc 
( 5  X 50 mL), giving light cream-colored 3a (789 mg, 78%). Anal. Calcd 
for C20H,,C12N302Pt: C, 39.16; H, 5.42; N,  6.85. Found: C, 39.1 I ;  H,  
5.74; N,  6.71. 
The ethyl acetate solution from triturations was concentrated. The 
yellow residue of irans-[PtCI2(NH3)(am)] ( 4 4  was triturated with ether 
(50 mg, 5%). Anal. Calcd for CmHMCI2NzO2Pt: C, 40.28; H, 5.07; N, 
4.70. Found: C, 40.53; H,  5.36; N,  4.82. 
The insoluble tetraamine complex [Pt(NH3),(am)]C12 (Sa) could not 
be purified. Anal. Calcd for C20H36C12N402Pt: C, 38.10; H,  5.76; N,  
8.89. Found: C, 35.59; H, 5.75; N,  9.10. 
[PtCI(NH,),(rm)ICl (3b) and tmm-[PtCI,(NH,)(am)] (4b) were 
prepared as described for 3r and 4a using ligand lb .  Compound 3b was 
obtained in 80% yield and dried for 48 h in high vacuum at  60 'C and 
8 h at 70 "C. Anal. Calcd for CmH35C12N302Pt~l/4CH3C02C2HS: C, 
39.56; H, 5.85; N,  6.59. Found: C,  39.30; H,  6.02; N,  6.38. Complex 
4b was isolated from ethyl acetate solution. Anal. Calcd for 
C20H32C12N202Pt: C, 40.14; H, 5.39; N,  4.68. Found: C, 39.68; H,  
5.61; N,  4.77. 
3b was also prepared by stirring cis-PtC12(NH3)2 (60 mg, 0.2 mmol) 
with AgNO, (33.9 mg, 0.2 mmol) in dry DMF (20 mL) at  ambient 
temperature in darkness for 15 h. After removal of AgCl by centrifu- 
gation, l b  (63 mg, 0.2 mmol) was added and the reaction mixture left 
for 48 h under N2. The solvent was removed in vacuum and the residue 
triturated with ethyl acetate ( 5  X 20 mL), redissolved in minimum DMF, 
and precipitated with ethyl acetate, yielding 3b, 99 mg, 80%. 
In Vitro Chemosensitivity Testing. Cell Line and Culture Conditions. 
The hormone sensitive MCF-7 (ATCC No. HTB 22) human breast 
cancer cell lineI6 was obtained from the American Type Culture Col- 
lection (ATCC) (Rockville, MD). Cell line banking and quality control 
was performed according to the "seed stock concept" reviewed by Hay.17 
The cells were routinely maintained in Eagle's medium (Sigma, 
Munchen, FRG) containing L-glutamine, NaHCO, (2.2 g/L), sodium 
pyruvate (1 IO mg/L), 50 mg/L gentamycin (Sebio, Walchsing, FRG), 
and 10% fetal calf serum (Gibco, Eggenheim, FRG). The cells were 
serially passaged weekly after trypsinization with trypsin (O.OS%)/EDTA 
(0.02%) (Boehringer, Mannheim, FRG) and cultured in a water-satu- 
rated atmosphere of 95% air and 5% carbon dioxide at  37 OC in 75-cm3 
flasks (Falcon Plastics 3023, Heidelberg, FRG). Cells were routinely 
monitored for, and shown to be free of, Mycoplasma contamination.'* 
Drugs Used as Positive Controls. Cisplatinum (Gold Label) was 
obtained from Aldrich (Steinheim, FRG) and Tamoxifen (citrate salt) 
was purchased from Sigma (Munchen, FRG). 
Kinetic Crystal Violet Assay. The detailed procedure has been de- 
scribed and evaluated e1se~here.I~ Briefly, the cells (passage 187 from 
origin) were seeded (100 pL/well) in 96-well flat-bottomed microtitration 
plates (Falcon Plastics 3075, Heidelberg, FRG) at  an appropriate density 
of ca. 15 cells per microscopic field (Leitz, Diavert, 320X). After 48 h, 
the medium was carefully removed by suction and replaced by fresh 
medium (200 pL/well) containing drug (drugs were added as a 1000-fold 
concentrated stock solution) or pure solvent. The platinum complexes 
were dissolved in DMF; the stock solutions of Tamoxifen were prepared 
with 70% (v/v) EtOH. On every plate, rows 5 and 6 (n = 16) served as 
controls (containing the appropriate solvent), whereas two vertical rows 
(n = 16) per drug concentration were used. After various times of 
incubation, the culture medium was shaken off and the cells were fixed 
with 100 pL of 1% glutardialdehyde in PBS per well for 15  min. The 
fixative was replaced by 150 pL of PBS per well and the plates were 
stored in the refrigerator (4 OC). At the end of the experiment all trays 
were stained simultaneously with 0.02% aqueous crystal violet solution 
(100 pL/well) for 30 min. Excess dye was removed by rinsing the trays 
with water for 15  min. The stain bound by the cells was redissolved in 
70% ethanol (180 pL/well). Absorbance was measured at  578 nm by 
using a BIOTEK 309 Autoreader (Tecnomara, Fernwald, FRG). 
Drug Action. Drug effects were expressed as corrected TIC values 
for each group according to 
(T/C),, = ( T -  Co)/(C- Co) X 100 [%I 
Notes 
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Jennerwein. M. J. Cancer Res. CNn. Oncol. 1990,116,237. (c) Bern- 
hardt, G.; Reile, H.; B i r n k k ,  H.; Spruss, T.; Schbnenberger, H. 
Submitted for publication in Cancer Res. 
where T is the mean absorbance of the treated cells, C is the mean 
absorbance of the controls, and C, is the mean absorbance a t  the time 
( i  = 0) when drug was added. The calculated experimental errors for 
T/C, (according to the Gaussian formula) amounted to about 10% after 
prolonged times of incubation. 
Results and Discussion 
3-(2-Aminoethoxy)estrone (la) and 3-(2-aminoethoxy)estradiol 
(lb)9 react with K[PtC13(NH3)] in DMF solutions at 70-80 OC 
over 4 h to form the yellow neutral mixed-amine complexes 
cis-[PtClz(NH3)(am)] (2) (eq 1). The reaction of 1 with cis- 
[PtCl,(NH,),] to yield the cationic complexes cis-[PtCl- 
(NH,),(am)]Cl (3) (eq 2) requires a longer reaction period and 
is accompanied by formation of truns-[PtCl,(NH,)(am)] (4) and 
the insoluble tetraamine complex [Pt(NH3),(am)]CI2 (5), probably 
via a bimolecular reaction of 3 (eq 3), which may explain the trans 
configuration of 4 (see Scheme I). Higher temperatures or a long 
reaction period favor this disproportionation. Lippert has found 
that the cationic complex cis-[PtCl(NH3),L]C1 (L = I-methyl- 
cytosine) releases ammonia at room temperature in aqueous so- 
lutions with formation of t r ~ n s - [ P t C l ~ ( N H ~ ) L ] . ~ ~  This reaction 
was first observed in mass spectroscopic studies.2' Lippert has 
shown that the release of ammonia is not restricted to nucleobase 
complexes; truns-[PtCl,(NH,),] is formed as well from aqueous 
solutions of [PtCI(NH3)3]C1.1'8 
Scheme I 
am + K[PtC13(NH3)] cis-[PtCl,(NH,)(am)] (1) 
1 + cis-[PtCl,(NH3),] - ~is-[PtCl(NH,)~(am)]Cl (2) 1 2 
3 
2 cis-[PtC1(NH3),(am)]C1 - 
3 
truns-[PtC1,(NH3)(am)] + [Pt(NH3),(am)]C1, (3) 
4 5 
DMF 
cis-[PtC1,(NH3),] + AgN03 - ~ i s - [ P t ( N H ~ ) ~ C l ( N 0 ~ ) 1  
6 + cis-[Pt(NH,),(DMF)Cl]Cl + AgCl (4) 
( 5 )  
7 







l a  I b  
We chose DMF as solvent, which, according to Kong and 
Rochon's suggestion, improves solubility and affects favorably the 
desired equilibria." By using DMF as a solvent, Passini improved 
the yield of anionic complexes.lk 3b was also prepared by a 
two-step reaction sequence: cis-[PtCl,(NH,),] was treated with 
1 equiv of AgN03 in DMF to form, according to Hollis,"b a 
mixture of active species C ~ ~ - [ P ~ ( N H ~ ) ~ ( D M F ) C ~ ] +  and cis- 
[Pt(NH,),(NO,)Cl], which subsequently react with lb. Traces 
of 4b were detected as well. 
The separation of 3 and 5 is easy since the tetraamine complex 
5 is insoluble in any organic solvent, whereas the less polar trans 
isomer 4, unlike the cis isomer 2, is soluble in EtOAc. 
All complexes exhibit in their IR spectra NH stretching ab- 
sorptions at 3400-3100 cm-', aliphatic CH bands of hormone 
skeleton at 2920 and 2850 cm-I, the C=O stretching of estrone 
(20) Lippert, B.; Lock, C. J. L.; Sperazini, R. A. Inorg. Chem. 1981,20,808. 
(21) Rms, 1. A. G.; Thomson, A. J.; Eagles, J. Chem.-Biol. Interact. 1974. 
8. 421. 
(22) Kong, P. C.; Rochon, F. D. J.  Chem. Soc., Chem. Commun. 1975,599. 
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Tabk I. Selected Spectroscopic Data for 3-(2-Aminoethoxy)estrogens and Their Platinum(I1) Complexes 
u(Pt-Cl),' WH)? ppm 
compound no. 18-CH benzylic CHzN CHzO aromatic 6( I95Pt)? ppm cm-I 
am 18 0.82 2.80 2.80 3.93 6.63 6.73 7.18 
am l b  0.74 2.78 2.90 3.93 6.63 6.73 7.18 
cis-[PtCI,(NH,)(am)] 21 0.82 2.76 3.22 4.25 6.69 6.75 7.21 322 m 
cis-[PtCIz(NH3)2(am)] 2b 0.75 2.78 3.14 4.29 6.61 6.78 7.22 -2171 322 m 
326 w, br 
cis-[PtCI(NH,),(am)]CI 3b 0.75 2.80 3.18 4.27 6.69 6.78 7.22 326 w, br 
rram-[PtCI,(NH,)(am)] 48 0.88 2.84 3.09 4.28 6.71 6.79 7.21 330 w, br 
330 w, br 
'NMR spectra were recorded in DMF-d,; standard TMS. *External standard: b(195Pt) of KzPtC16 in Dz0.26 CIR spectra taken as KBr disks. 
~is-[PtCl(NH,)~(am)]Cl 3a 0.82 2.80 3.20 4.20 6.65 6.70 7.18 -2023 
rram-[PtCI,(NH,)(am)] 4b 0.75 2.75 3.08 4.20 6.32 6.69 7.18 -2 178 
MCF-7, 188.Pass. 
Kinetics of Growth 
0 50 100 150 200 250 
Incubation Time [h] 
Figure 1. Growth curves of MCF-7 cells (in passage 188) used as 
"untreated" controls in the chemosensitivity assay. The medium con- 
tained no drug but contained the solvents EtOH or DMF. 
a t  1735 cm-I, and aromatic C-C bands a t  1605 cm-I. The 
isomers k , b  and 4a,b differ in their Pt-Cl absorptions. The Pt-Cl 
band of the cis isomers 2a,b appears a t  322 cm-' whereas that 
of the trans-4a,b is observed a t  330 cm-I. A similar difference 
has been found for cis- and t r ~ n s - P t C l ~ ( N H , ) ~ . ~ ~ * ~ ~  In the 'H 
NMR spectra (Table I) of the complexes as in the parent hor- 
mones, 18-CH3 appears at 0.82 ppm (am = la) and at 0.75 ppm 
(am = lb), respectively. The skeleton protons are spread between 
1.1 and 2.4 ppm. Benzylic protons at 2.7-2.8 ppm partially overlap 
with those of DMF-d,. Aromatic protons I-CH and 2-CH form 
a AB pattern (J = 8.5 Hz); 2-CH has a long-range coupling with 
4-CH (J = 1.5 Hz) (see Table I). These similarities rule out a 
metal-catalyzed rearrangement of the ligand during formation 
of the complexes. The main differences are observed in the 
chemical shifts of the aminoethoxy group. In the free ligand, 
CH2N appears as a quartet around 2.90 ppm and CHzO appears 
as a triplet at 3.90 ppm (J = 5.5 ppm), whereas in the complexes 
CH2N protons are shifted to 3.10-3.20 ppm and become very 
broad. CHIO protons are shifted to the 4.10-4.20 ppm region 
and overlap with a part of the Pt-NH protons. 
The I3C NMR spectra of the complexes are similar to those 
of the corresponding ligands. The assignment of all carbons is 
not possible owing to the overlap with DMF-d7 carbons, and 
information about the difference between the coordinated and 
uncoordinated CH2NH2 group is not available. 
In the 195Pt NMR spectra, the difference in chemical shifts of 
cis and trans isomers is 7 ppm. Farrell and QuZ5 observed 4 ppm 
(23) Denning, R. G.; Ware, M. J. Spectrochim. Acta 1968, 21A, 1785. 
(24) Nakamoto, K.; McCarthy, P. J.; Fujita, J.; Condratc. R. A.; Behnke, 
G. T. Inorg. Chem. 1%5,4, 36. 
(25) Farrell, N.; Qu. Y .  Inorg. Chem. 1989, 28, 3416. 
(26) Pregosin. P. S. Annu. Rep. NMR Spectrosc. 1986, 17, 285. 
MCF-7, 188.Pass. 
Long Tlme Incubation of Tamoxlten 
'l*H 
-20 - - 
0 M ) l O o l M ) 2 M ) 2 5 0  
Incubation Time [h] 
I conc. 1.1 0 - 7 ~  e conc. 1.10.5M conc. 1.10.6M 
Figure 2. Effect of Tamoxifen on the hormone-sensitive human breast 
cancer cell line MCF-7. Plots are of corrected TICvalues versus time 
of drug exposure. 
MCF-7,188.Pa~s. 
Long Time Incubation of cDDP 
0 5 0 1 O o l W M 0 2 # )  
Incubation Time [hl 
e conc. 5.107M 
conc. 1 .I o - 6 ~  
e conc. 5.10-% 
Figure 3. Effect of Cisplatinum on the hormone-sensitive human breast 
cancer cell line MCF-7 plotted as in Figure 2. 
difference between binuclear diamine cis and trans complexes (in 
DMF). A 148 ppm difference is observed between the neutral 
2b and the positively charged 3a, as compared to 200 ppm for 
[PtC1(NH3)2(pyridine)]+.11b 
Conductivity of the ionic complexes 3a and 3b in DMF was 
57 and 54 $3 respectively, as compared with 2-5 pS for the free 
ligands and for 2a, 2b, 4a, and 4b. 
Antitumor Tests. Figure 1 illustrates the effect of the solvents 
DMF and EtOH (used as vehicles for Cisplatin, the complexes 
2b and 3b, and the partial antiestrogen Tamoxifen) on the pro- 
4088 Inorg. Chem. 1991,30, 4088-4093 
MCF-7, 188.PaSS. 
Long Time Incubation of 2b 
0 60 1w 160 200 260 
Incubation Time [h] 
I conc. 5.10-7M e conc. 5.104M I conc. 1,10-%4 
Figure 4. Effect of 2b on the hormone-sensitive human breast cancer cell 
line MCF-7 plotted as in Figure 2. 
MCF-7, 188.Pass. 
Long Time Incubation of 3b 
140, I I I I 1 
TIC 
-20 IlzBzl 0 60 1 w 1 5 o m 2 # )  
Incubation Time [hl 
cone. 5 . 1 0 - 7 ~  e conc. 5.104Y 
conc. 1.106M 
Figure 5. Effect of 34 on the hormone-sensitive human breast cancer cell 
line MCF-7 plotted as in Figure 2. 
liferation kinetics of MCF-7. Cell proliferation is not significantly 
affected by the nature of the organic solvent. The results of the 
in vitro chemosensitivity tests against MCF-7 are summarized 
in Figures 2-5. Figure 2 demonstrates that cell proliferation is 
inhibited by IO-$ M Tamoxifen, a clinically established drug in 
the hormonal treatment of breast cancer. The hormone-sensitive 
cell line was also inhibited by Cisplatinum (Figure 3). Within 
the selected concentration range ( 5  X lo-', 1 X lo", and 5 X lod 
M) inhibition was clearly dose-related. No effect was observed 
for the neutral Pt complex [PtCI2(NH3)(am)] (2b) (Figure 4), 
whereas the cationic compound cis-[PtCI(NH3),(am)]Cl (3b) was 
cytostatic in a concentration of 5 X lod M with a final TIC,, 
value of around 40% (Figure 5 ) .  The extent of inhibition is 
comparable with the effect of Tamoxifen. Although we observed 
a marked antiproliferative effect on the estrogen receptor positive 
cell line MCF-7, a direct hormonal action seems unlikely because 
of the cytotoxic potential of 3b against the L 1210 leukemia of 
the mouse. According to the generally accepted mechanism of 
action for platinum anticancer drugs, the positively charged 
complex must have crossed the cell membrane prior to cross-link 
formation with the bases of the DNA. Both compounds 2b and 
3b showed activity against the L 1210 cell line of the mouse (EC 
90 = 0.3 ccg/mL, 6 days exposure). Complex 3b was also active 
in vivo (P388; 46.4 mg/kg: TIC = 150%; LDu, = 158 mg/kg). 
Compound 3a showed ED 90 > 1 pg/mL (L 1210). 
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Introduction 
Comparatively few detailed investigations of the EPR spectra 
of low-spin iron(II1) complexes have been undertaken,'? and for 
those compounds which have been studied, the interpretation of 
their spectra has been complicated by the fact that the g values 
are very sensitive to the splitting of the ,T2, ground state. This 
may be difficult to estimate, as the 2T, state is both Jahn-Teller 
unstable and strongly influenced by the *-bonding properties of 
the ligands. Past studies have sometimes required orbital reduction 
factors greater than unity, which is chemically unreasonable unless 
the parameters are modified to include the effects of configuration 
intera~tion.~ 
Recently, the preparation of a novel complex of iron(II1) with 
the sexidentate ligand 6,13-dimethyl- 1,4,8,1 l-tetraazacyclotet- 
radecane413-diamine (diammac), was reported.' The geometry 
of the cation [Fe(diamma~)](ClO~)~ is shown in Figure 1. This 
provides an ideal system to investigate the relationship between 
the g tensor and the metal-ligand bonding parameters of a low-spin 
iron( 111) complex, since simple bonding considerations suggest 
that *-bonding interactions with a saturated amine of this kind 
should be negligible. Moreover, the unit cell of [Fe(diam- 
mac)] (C104)3 contains two complex cations in the asymmetric 
unit, possessing slightly different geometries: which allows the 
influence of changes in the stereochemistry upon the EPR spec- 
trum to be probed. In contrast to previous studies in which 
perturbation formulas have been used to relate the g values to 
the energies of higher states,' in the current work the g tensors 
are interpreted by carrying out calculations using the computer 
program CAMMAG, extended to treat the complete dS basis set. 
This program, developed in its original version by Gerloch and 
co-workers,5 has recently been used to successfully interpret the 
energy levels and g values of a wide range of transition-metal 
complexes within the framework of the angular overlap model 
(AOM).6 The present paper reports the single-crystal EPR 
spectrum of [Fe(diamma~)](ClO,)~. The g tensors of the two 
[Fe(diammac)13+ units present in the complex are interpreted and 
compared with those reported for other polyamine complexes of 
Fe(II1). 
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